Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
Lymphoma
Milton S. Hershey Medical CenterCell therapyPhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 65/ 100
Competitive context
289 Active assets in the Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINBLASTINE Intensity Therapeutics, Inc. | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation | Phase 4 | BBB |
BLEOMYCIN Shandong Provincial Hospital | Phase 4 | BB |
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
(+)-VINCRISTINE Beth Israel Deaconess Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderDormant
CC
Indicative ·
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →